Epcoritamab for Lymphoma, Follicular

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Lymphoma, Follicular+2 More
Epcoritamab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) Follicular Lymphoma (FL).

Eligible Conditions
  • Lymphoma, Follicular

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Lymphoma, Follicular

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Up to approximately 8 years from randomization

Year 5
Percentage of Participants Achieving Best Overall Response (BOR)
Percentage of Participants Achieving Complete Response (CR)
Percentage of Participants Achieving Minimal Residual Disease (MRD) Negativity
Progression-Free Survival (PFS)
Year 8
Overall Survival (OS)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Lymphoma, Follicular

Trial Design

3 Treatment Groups

Lenalidomide and Rituximab (R2)
1 of 3
Epcoritamab Dose A in Combination With R2
1 of 3
Epcoritamab Dose B in Combination With R2
1 of 3
Active Control
Experimental Treatment

642 Total Participants · 3 Treatment Groups

Primary Treatment: Epcoritamab · No Placebo Group · Phase 3

Epcoritamab Dose A in Combination With R2Experimental Group · 3 Interventions: Rituximab, Epcoritamab, Lenalidomide · Intervention Types: Drug, Drug, Drug
Epcoritamab Dose B in Combination With R2Experimental Group · 3 Interventions: Rituximab, Epcoritamab, Lenalidomide · Intervention Types: Drug, Drug, Drug
Lenalidomide and Rituximab (R2)ActiveComparator Group · 2 Interventions: Rituximab, Lenalidomide · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
1999
Completed Phase 4
~1880
Lenalidomide
2005
Completed Phase 3
~1590

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 8 years from randomization

Who is running the clinical trial?

GenmabIndustry Sponsor
42 Previous Clinical Trials
7,552 Total Patients Enrolled
1 Trials studying Lymphoma, Follicular
80 Patients Enrolled for Lymphoma, Follicular
AbbVieLead Sponsor
822 Previous Clinical Trials
468,963 Total Patients Enrolled
4 Trials studying Lymphoma, Follicular
398 Patients Enrolled for Lymphoma, Follicular
ABBVIE INC.Study DirectorAbbVie
295 Previous Clinical Trials
116,507 Total Patients Enrolled
2 Trials studying Lymphoma, Follicular
194 Patients Enrolled for Lymphoma, Follicular

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a performance status of 0 to 2.
You have ≥ 1 measurable lesion or extra-nodal lesion on CT scan or MRI.
You have follicular lymphoma (FL) with no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy and CD20+ on a representative tumor biopsy based on the pathology report.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: October 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.